Journal
DRUG DISCOVERY TODAY
Volume 16, Issue 17-18, Pages 810-816Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2011.06.003
Keywords
-
Categories
Funding
- Science Foundation Ireland
- EU
- European Community
Ask authors/readers for more resources
The HER2 receptor is currently one of the flagship therapeutic targets in clinical oncology. Trastuzumab, an antibody targeting HER2, has become a foundation of care in women with HER2-positive breast cancer. However, many women with metastatic breast cancer do not respond to trastuzumab-based therapy. One possible source of trastuzumab resistance is the presence of truncated forms of HER2 in the tumor. Numerous studies suggest that detection of truncated HER2 in the tumor should result in modification of the classical therapeutic approach. Recent development of several promising compounds brings hope that a generation of novel therapeutic modalities against HER2-positive cancers will be delivered in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available